TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

51 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Depression

    The Role of mGluR5 in CBT-I

    Testing how a brain receptor may affect CBT-I for insomnia in people with depression

    📍 Stony Brook University: Dept of Psychiatry · Stony Brook, NY · Get directions →

    This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Molecular Signatures of Cutaneous Dupilumab Response

    Studying how dupilumab affects immune cells in eczema skin

    📍 University of California, San Francisco · San Francisco, CA · Get directions →

    This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Depression

    Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression

    Testing brain scan and EEG measures to predict response to depression treatment

    📍 Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 · Austin, TX · Get directions →

    The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Depression

    Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures

    Testing how feasible it is to prescribe antidepressants after fragility fractures in adults 50 and

    📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →

    The goal of this pilot study is to learn about the feasibility about prescribing anti-depressants at discharge in patients aged 50 years and older with a lower extremity fragility fracture. The main questions it aims to answer are: * What are the obstacles to enrolling patients and prescribing anti-depressants among older adults?

    ✓ Study care freePhase 4Ages 65+Learn more →
  • Multiple sclerosis (MS)

    Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

    Testing safety of a twice-yearly medicine for early relapsing MS

    📍 Northwestern Memorial Hospital · Chicago, IL · Get directions →

    In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Depression

    Dopaminergic Therapy for Anhedonia - 2

    Testing an 8-week treatment using L-DOPA for depression with low pleasure and high inflammation

    📍 Emory University Hospital · Atlanta, GA · Get directions →

    The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks.

    ✓ Study care freePhase 4Ages 25–55Learn more →
  • Kidney disease

    Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

    Testing whether empagliflozin changes kidney filter injury proteins in African American Veterans

    📍 Washington DC Veterans Affairs Medical Center (688) · Washington D.C., DC · Get directions →

    Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.

    ✓ Study care freePhase 4Ages 19–90Learn more →
  • Depression

    Identifying and Treating Depression in the Orthopaedic Trauma Population

    Testing how orthopedic trauma teams can screen for depression and treat it with medication

    📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →

    The goal of this trial is to pilot a way for orthopaedic surgeons to safely screen for depression and provide treatment for depression with medication. The main questions it aims to answer are: 1.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

    Testing whether combining a walking medication with physical therapy improves mobility in people

    📍 MGH Institute of Health Professions · Boston, MA · Get directions →

    The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?

    ✓ Study care freePhase 4Ages 25–75Learn more →
  • Kidney disease

    Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

    Testing kidney disease drug effects and safety in teens with early CKD

    💵 May compensate

    📍 Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes · Aguascalientes, Aguascalientes · Get directions →

    Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.

    ✓ Study care freePhase 4Ages 14–18Learn more →
  • Eczema / atopic dermatitis

    Dupilumab De-escalation in Pediatric Atopic Dermatitis

    Testing whether stopping or lowering eczema treatment works for kids

    📍 Johns Hopkins Univerisity · Baltimore, MD · Get directions →

    This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.

    ✓ Study care freePhase 4Ages 1–17Learn more →
  • Obesity / overweightHigh blood pressure

    Impact GLP-1 Agonists Following Bariatric

    Testing whether GLP-1 medicines after bariatric surgery affect weight and blood sugar

    📍 University of Missouri Hospital · Columbia, MO · Get directions →

    Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Kidney disease

    Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

    Testing whether two dialysate salt levels affect heart events and death

    📍 Royal Adelaide Hospital · Adelaide, · Get directions →

    This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Type 2 diabetesKidney disease

    Mechanism of SGLT2 Inhibition in the Kidney

    Testing how SGLT2 medicines affect kidney function in type 2 diabetes

    💵 May compensate

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Depression

    Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)

    Comparing best step-by-step treatments for depression with anxiety

    📍 University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience · Cincinnati, OH · Get directions →

    Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.

    ✓ Study care freePhase 4Ages 18–50Learn more →
  • Multiple sclerosis (MS)

    Home Based Infusions for Ocrelizumab

    Testing the safety and effectiveness of home infusions of ocrelizumab for multiple sclerosis

    📍 Amerita · Centennial, CO · Get directions →

    The goal is to assess the safety and effectiveness of home ocrelizumab infusion.

    ✓ Study care freePhase 4Ages 18–55Learn more →
  • Depression

    Neural Circuit Effects of Ketamine in Depression

    Testing how ketamine affects brain activity and depression symptoms

    📍 Icahn School of Medicine at Mount Sinai · New York, NY · Get directions →

    This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Eczema / atopic dermatitis

    Lebrikizumab in Moderate-to-severe Atopic Dermatitis

    Testing a medicine called lebrikizumab for long-term improvement in eczema

    📍 Physioseq USA - CA · Folsom, CA · +1 more US site · Get directions →

    This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Depression

    A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

    Comparing a drug called AXS-05 with bupropion to prevent depression relapse

    📍 Clinical Research Site · Bellflower, CA · +39 more US sites · Get directions →

    This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • DepressionDementia / Alzheimer's

    Aβ Dynamics in LLMD

    Testing how treating depression may change brain markers linked to Alzheimer’s

    📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →

    This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers.

    ✓ Study care freePhase 4Ages 60+Learn more →
  • Depression

    Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

    Testing a biomarker prediction tool to forecast depression treatment outcomes

    📍 University of Calgary · Calgary, Alberta · Get directions →

    This is a study that will test a predictive biomarker algorithm based on results from a previous study. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Eczema / atopic dermatitis

    Ethnic Differences in Mechanisms of Action of Dupilumab

    Studying how a common eczema treatment works differently by race

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

    Testing whether ozanimod is safe and works as a step-down treatment for stable multiple sclerosis

    💵 May compensate

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · +2 more US sites · Get directions →

    A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

    Testing whether switching from ocrelizumab to ublituximab helps MS symptoms that return

    📍 Johns Hopkins University · Baltimore, MD · Get directions →

    The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Obesity / overweightHigh blood pressure

    Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

    Testing treatments to lower high pressure in liver veins in people with advanced liver disease and

    💵 May compensate

    📍 Cleveland Clinic Main Campus · Cleveland, OH · Get directions →

    Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Depression

    Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

    Studying how menstrual hormone changes affect mood and reward in women with depression

    📍 University of North Carolina, Chapel Hill · Chapel Hill, NC · Get directions →

    The goal of this clinical trial is to learn how hormonal changes over the menstrual cycle affect mood symptoms in reproductive-aged women with depression that worsens during the premenstrual period. The main questions it aims to answer are: --How do fluctuations in estradiol and progesterone across the menstrual cycle affect the ability to experience pleasure and the neural sensitivity to reward in hormone-sensitive, depressed women?

    ✓ Study care freePhase 4Ages 18–45WomenLearn more →
  • Multiple sclerosis (MS)

    Glucose Consumption in MS Using [F-18]FDG-PET

    Testing how [F-18]FDG PET shows glucose use in people with MS and controls

    📍 Brigham & Women's Hospital · Boston, MA · Get directions →

    Given the need for better diagnostic imaging techniques in multiple sclerosis (MS), the study aims to investigate the utility of \[F-18\]FDG positron emission tomography (PET) in MS. The study will be assessing glucose consumption patterns in subjects with progressive MS (PMS) and relapsing-remitting MS (RRMS), as well as healthy controls.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Depression

    PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

    Testing PET brain scans to study how nicotine may affect depression

    📍 Stony Brook University: Dept of Psychiatry · Stony Brook, NY · Get directions →

    In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Depression

    📍 Neurocrine Clinical Site · Bryant, AR · +21 more US sites · Get directions →

    This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis

    Testing whether silodosin helps lower urinary tract symptoms in women with multiple sclerosis

    📍 Atlantic Health · Morristown, NJ · Get directions →

    The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Multiple sclerosis (MS)

    ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

    Testing eye-tracking measures to track disease changes in relapsing-remitting multiple sclerosis

    📍 Novartis Investigative Site · Calgary, Alberta · Get directions →

    The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.

    ✓ Study care freePhase 4Ages 18–99Learn more →
  • Kidney disease

    Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

    Testing whether a weekly diabetes medicine is safe for people on dialysis

    📍 Unity Health Toronto · Toronto, Ontario · Get directions →

    This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Depression

    Esketamine With or Without Integration Therapy for Treatment-Resistant Depression

    Testing whether nasal esketamine with or without therapy helps adults with depression that hasn’t

    📍 Pravan Foundation · San Juan, · Get directions →

    This study will explore the effects of esketamine (Spravato®), an FDA-approved nasal spray, on adults diagnosed with treatment-resistant depression (TRD). All participants will receive esketamine as prescribed by a healthcare professional in a clinical setting.

    ✓ Study care freePhase 4Ages 21–65Learn more →
  • Obesity / overweightKidney disease

    Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

    Studying weight-loss support for people with obesity and kidney disease who want a kidney transplant

    📍 London Health Sciences Centre · London, Ontario · Get directions →

    OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Depression

    Personalized Indications for CBT and Antidepressants in Treating Depression

    Testing how cognitive-behavioral therapy and antidepressant use can be matched for people with

    📍 Nova Scotia Health Authority · Halifax, Nova Scotia · Get directions →

    Depression currently affects close to 2 million Canadians and is the leading cause of disability worldwide. Pharmacological treatments (antidepressant medication) and psychological treatments such as cognitive-behavioural therapy are available for depression, but the majority of those who receive treatment have an unsatisfactory response.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Depression

    ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression

    Testing whether high-intensity ketamine with ECT rescue works better than ECT with ketamine

    📍 Royal University Hospital · Saskatoon, Saskatchewan · Get directions →

    To determine if an high intensity ketamine with ECT rescue (HIKER) approach for treatment resistant depression will: 1) reduce patient suffering by hastening disease remission, 2) have fewer side effects, 3) reduce the need for ECT, and 4) be preferred by most patients. Half of participants will be randomized to the HIKER arm and receive high intensity ketamine treatment for eight consecutive days, and the other half will be assigned to the ECT with ketamine anesthesia (EAST) arm and receive 8 ECT treatments (2-3 treatment/week)

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

    Testing stopping ocrelizumab in people with relapsing multiple sclerosis

    📍 Yale School of Medicine · New Haven, CT · +12 more US sites · Get directions →

    This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6,12, 18, and 24.

    ✓ Study care freePhase 4Ages 18–55Learn more →
  • Depression

    RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

    Testing whether RNA changes predict response to depression treatment

    📍 Mayo Clinic in Rochester · Rochester, MN · Get directions →

    The purpose of this research is to understand how changes in RNA editing relate to treatment response in unipolar and bipolar depression.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Depression

    Establishing Mobile Transcranial Magnetic Stimulation

    Testing a portable brain-stimulation device for treating depression

    📍 Medical Univerity of South Carolina · Charleston, SC · Get directions →

    In this pilot study, investigators propose to design and create a portable TMS unit, in a van, and then test out delivering TMS in three different locations in South Carolina, all affiliated with MUSC and within 2-hours driving from Charleston, SC. This study would test out this new delivery mode, and provide valuable feasibility, safety, and efficacy lessons for later refinement and potential widespread adoption of mobile TMS as a treatment option, both in our state and across the US.

    ✓ Study care freePhase 4Ages 22–80Learn more →
  • DepressionAnxiety

    Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

    Studying brain circuits for threat sensitivity in people with anxiety and depression

    📍 Laureate Institute for Brain Research · Tulsa, OK · Get directions →

    This mechanistic study uses an anti anxiety drug and brain imaging to study the threat processing system and associated brain circuits in people with depression, anxiety disorders and comorbid depression and anxiety disorders. In a double blind, placebo controlled crossover design, up to 65 individuals will be recruited who will have a diagnosis of major depressive disorder (MDD) and at least one anxiety disorder (AD) (AD-MDD group), up to 65 participants will have a diagnosis of MDD and no diagnosis of an AD and up to 65 participants will have no diagnosis of MDD and a diagnosis of at least one AD will be enrolled to participate in an two session study to obtain 150 completers (50 per group).

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Kidney disease

    Empagliflozin Treatment in Kidney Transplant Recipients

    Testing empagliflozin in people with kidney transplants and chronic kidney disease

    📍 Edward Hines Jr. VA Hospital, Hines, IL · Hines, IL · +4 more US sites · Get directions →

    Kidney transplantation improves the health and quality of life for those Veterans with end stage kidney disease (ESKD). While early patient and graft survival are excellent, long-term outcomes continue to be challenging.

    ✓ Study care freePhase 4Ages 19+Learn more →
  • Kidney disease

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

    Testing whether pioglitazone can reduce overactive nerve activity in people with chronic kidney

    📍 University of Texas at Arlington · Arlington, TX · +1 more US site · Get directions →

    Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population.

    ✓ Study care freePhase 4Ages 35–70Learn more →
  • Kidney disease

    Oral Iron in Children With Chronic Kidney Disease

    Testing oral iron in children with chronic kidney disease and mild anemia

    📍 Weill Cornell Medicine / New York Presbyterian Hospital · New York, NY · +1 more US site · Get directions →

    This is a pilot clinical trial of oral iron therapy in children with chronic kidney disease (CKD) and mild anemia. Eligible children will be randomized into a standard of care (iron sulfate) arm vs.

    ✓ Study care freePhase 4Ages 1–21Learn more →
  • DepressionAnxiety

    Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)

    Testing antidepressant treatment for anxious teens with anxiety and depression

    📍 University of Cincinnati · Cincinnati, OH · Get directions →

    Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by open-label naturalistic follow-up.

    ✓ Study care freePhase 4Ages 12–17Learn more →
  • Depression

    Buspirone and Melatonin for Depression Following Traumatic Brain Injury

    Testing buspirone and melatonin for depression after a traumatic brain injury

    📍 Massachusetts General Hospital · Boston, MA · +1 more US site · Get directions →

    Traumatic brain injuries (TBIs) are common. Post-TBI depression is associated with anxiety, aggression, fatigue, distractibility, anger, irritability, and rumination.

    ✓ Study care freePhase 4Ages 18–64Learn more →
  • Eczema / atopic dermatitis

    Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

    Testing how dupilumab affects sleep, itching, and body clock in children with moderate to severe

    📍 Lurie Children's Hospital/Northwestern University · Chicago, IL · Get directions →

    Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old

    ✓ Study care freePhase 4Ages 6–17Learn more →
  • Depression

    Examining the Effects of Estradiol on Neural and Molecular Response to Reward

    Testing whether estradiol affects depression symptoms tied to reward

    📍 University of North Carolina at Chapel Hill · Chapel Hill, NC · Get directions →

    This proposal will examine the effects of estradiol administration on perimenopausal-onset (PO) anhedonia and psychosis symptoms as well as on brain function using simultaneous positron emission tomography and functional magnetic resonance imaging (PET-MR).

    ✓ Study care freePhase 4Ages 45–55WomenLearn more →
  • Eczema / atopic dermatitis

    Dupixent and Narrowband UVB for Atopic Dermatitis

    Testing dupilumab plus narrowband UVB light for eczema over 24 weeks

    📍 Eczema Treatment Center of New Jersey · East Windsor, NJ · Get directions →

    24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Depression

    Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression

    Testing whether ketamine or esketamine helps prevent suicide in people with depression

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    The study will consist of a 24-week-long trial examining outcomes in patients with Major Depressive Disorder and suicidal ideation who will receive intravenous (IV) ketamine and intranasal (IN) esketamine, compared to a large sample of matched historical controls. Patients will be recruited from an inpatient psychiatric unit.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Kidney disease

    Safety of Short-course of NSAIDs in Pediatric Patients With CKD

    Testing whether short courses of anti-inflammatory pain medicines after surgery raise kidney injury

    📍 Children's Hospital Colorado · Aurora, CO · Get directions →

    The purpose of this study is to determine if non-steroidal anti-inflammatory (NSAID) use in the postoperative setting increases the risk of acute kidney injury (AKI) in pediatric patients with mild-to-moderate chronic kidney disease (CKD). The investigators hypothesize that there is no increased risk.

    ✓ Study care freePhase 4Ages 2–25Learn more →
  • Depression

    Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients

    Testing ketamine given during surgery to improve pain and depression after serious bone injury

    📍 Texas Tech University Health Sciences Center Lubbock · Lubbock, TX · +1 more US site · Get directions →

    The goal of this clinical trial is to learn if ketamine, given during surgery, can help improve recovery for adults with serious orthopedic trauma. The study will test whether ketamine reduces pain, lowers the need for opioids, and improves mental health outcomes like depression and post-traumatic stress disorder (PTSD).

    ✓ Study care freePhase 4Ages 18–65Learn more →